# **Progress in Medical Virology**

Vol. 15

## Progress in Medical Virology

Vol. 15

Edited by Joseph L. Melnick, Houston, Tex.

Contributors: Kathleen Barrett, Berkeley, Calif.; Russell J. Blattner, Houston, Tex.; Richard Calendar, Berkeley, Calif.; W. Charles Cockburn, Genève; Donald L. Eddins, Atlanta, Ga.; William H. Foege, Atlanta, Ga.; James H. S. Gear, Johannesburg; Warren Gibbs, Berkeley, Calif.; Richard N. Goldstein, Berkeley, Calif.; Florence M. Heys, Houston, Tex.; Noboru Higashi, Kyoto; Edwin H. Lennette, Berkeley, Calif.; A. Martin Lerner, Detroit, Mich.; Bjorn Lindqvist, Iowa City, Ia.; Veronica Measroch, Johannesburg; Joseph L. Melnick, Houston, Tex.; Gordon Plummer, Maywood, Ill.; Nathalie J. Schmidt, Berkeley, Calif.; Erich Six, Iowa City, Ia.; Thomas G. Ward, Bethesda, Md.; Alice P. Williamson, Houston, Tex.; Francis M. Wilson, Detroit, Mich.

63 figures and 18 tables





S. Karger · Basel · München · Paris · London · New York · Sydney · 1973

### Progress in Medical Virology

```
Vol. 1
         VIII+302 p., 47 fig., 41 tab., 1958
Vol. 2
           VI+234 p., 36 fig., 23 tab., 1959
Vol. 3
         VIII+496 p., 59 fig., 40 tab., 1961
         VIII+303 p., 27 fig., 34 tab., 3 cpl., 1962
Vol. 4
Vol. 5
            X + 306 p., 29 fig., 10 tab., 1963
Vol. 6
            X+320 p., 23 fig., 12 tab., 1964
Vol. 7
          XII+376 p., 58 fig., 22 tab., 1965
Vol. 8
          XII + 420 p., 36 fig., 30 tab., 1966
         XIV+496 p., 53 fig., 92 tab., 1967
Vol. 10 XVIII + 502 p., 55 fig., 25 tab., 1 cpl., 1968
Vol. 11 XVIII+470 p., 120 fig., 45 tab., 1969
Vol. 12 XVIII+358 p., 56 fig., 26 tab., 1970
Vol. 13
          XX+503 p., 86 fig., 42 tab., 1971
Vol. 14
           X+339 p., 43 fig., 30 tab., 1972
```

S. Karger · Basel · München · Paris · London · New York · Sydney Arnold-Böcklin-Strasse 25, CH-4000 Basel 11 (Switzerland)

All rights, including that of translation into other languages, reserved. Photomechanic reproduction (photocopy, microcopy) of this book or parts thereof without special permission of the publishers is prohibited.

© Copyright 1973 by S. Karger AG, Verlag für Medizin und Naturwissenschaften, Basel Printed in Switzerland by F. Reinhardt AG, Basel ISBN 3-8055-1388-7

#### Preface

The first six volumes of this series are now out of print. Rather than reprinting these previous volumes, current volumes of the series will include, in addition to new articles, reviews on selected topics from the early volumes, rewritten and updated – most of them by the authors who contributed the previous reviews nine to fifteen years ago.

Although total fetal and infant morbidity and mortality have declined in recent years, the incidence of congenital malformations has remained high. It has been estimated that each year, in the USA alone, 500,000 fetal deaths and 62,000 neonatal deaths are associated with congenital defects, and about 15 million individuals who survived have birth defects severe enough to affect their daily lives. In this volume, BLATTNER, WILLIAMSON, and Heys up-date their review written more than a decade ago on the role of viruses in congenital malformations. The authors discuss important recent advances in the understanding and control of viral teratogenesis, particularly in understanding of rubella virus and of cytomegalovirus as teratogenes and of the previously unrecognized immunologic capabilities of the human fetus. Not only do they describe what has been learned to date, but they also point out important areas in which knowledge is incomplete and avenues of further investigation are promising, both in clinical investigations and in studies of experimental models in animals.

GEAR and MEASROCH review the status of knowledge concerning clinical illnesses, particularly of the newborn, which have been associated with coxsackievirus infections. This review is an up-dating of GEAR's review published in the first volume of this series, in 1958. In addition to surveying a number of outbreaks of severe illnesses due to coxsackieviruses of group A and of group B, the authors describe clinical, pathological and virological

Preface XIV

studies, and outline recommended preventive measures. The authors suggest that the future pattern of epidemiology of the coxsackieviruses may follow that of poliomyelitis, i.e., where once immunizing infection with the coxsackieviruses occurred in early life, improved standards of living and hygiene may lead to postponement of initial infections into older age groups, in whom overt illnesses may occur more frequently. They also predict an increase in the proportion of women of childbearing age who lack immunity to coxsackie B viruses, and a corresponding increase in the proportion of babies born without the protection of maternal antibody.

Although virus myocarditis was reviewed only 8 years ago, developments in this field have been so rapid that LERNER and WILSON were asked to survey advances that have taken place since that 1965 publication. At the time of the earlier review, it was generally accepted that, while acute human infections of the myocardium and/or pericardium with coxsackievirus B might take place, including occasional lethal infections in newborns, there were no known sequelae in man or animals. Today, group B coxsackievirus infections have been associated with acute myopericarditis, valvulitis, chronic myocardiopathy, constrictive pericarditis, vena caval obstructions, endocardial fibroelastosis, and other congenital malformations of the heart. Group A coxsackieviruses and echoviruses also are now implicated in some of these disorders, and there are suggestions that some cases of rheumatic heart disease or glomerulonephritis may be due to enteroviruses. The authors critically review more than 100 selected new reports, both of human infections and of experimental animal models, discuss the pathogenesis of acute and chronic virus-associated disorders of the heart, and examine the evidence for the virus-disease associations.

When the 1858 review entitled 'The salivary gland viruses of man and animals' by MARGARET G. SMITH appeared in this series, the agent had been transmitted in tissue cultures only a few years previously. Since that time, a large amount of information has been acquired about the salivary-gland viruses – or cytomegaloviruses, as they are now known. Cytomegaloviruses of a variety of host species have been recognized; the cytomegaloviruses of man have been studied with regard to their epidemiology, pathogenesis, and clinical effects – as have a number of the animal cytomegaloviruses. Cytomegaloviruses have been of special concern in recent years, not only because of their primary involvement in the serious cytomegalic inclusion disease which they can produce in congenitally infected infants, but also because their ability to establish congenital infections and persistent infections, like that of the other herpesviruses, attracted special attention in

Preface XV

the search for viral etiologic agents of cancer and of other chronic diseases of unknown etiology. In this volume, Plummer reviews the progress that has been made in these investigations, the effects that they have on their hosts, and their taxonomic relationship to the other herpesviruses.

Both isolations of viruses of the respiratory tract and data about these agents and the diseases which they cause have proliferated greatly over the years since 1959, when WARD reviewed these viruses in Volume 2 of this series. His current review deals particularly with the myxovirus groups, the rhinoviruses, the adenoviruses, and the coronaviruses, surveying the characteristics of the agents, and their clinical and epidemiologic features.

The growth of the field of virology, and the increasing numbers of virus laboratories around the world, have been paralleled by the steady development of the virus programs of the World Health Organization and its network of virus reference centres and collaborating laboratories. Cockburn, who reported to readers of this series in 1966 on the WHO program in medical virology, describes here the numerous and significant developments which have been achieved in the virologic activities of WHO since that time. The established role of WHO is to promote understanding of the epidemiology and ecology of virus diseases in a worldwide setting, in order to aid in control of these diseases. Particularly in recent years, WHO has stimulated laboratory and field studies and their application to public health problems. A part of the WHO program is implemented through the WHO Virus Reference Centres, which assist national laboratories in the identification of viruses, aid in furnishing reference and diagnostic reagents, assist in the training of national virologists, and participate in collaborative research studies conducted within the WHO network. Other important activities of the Virus Diseases Program include the regular collection and dissemination of epidemiological and virological information, aid in epidemic situations, and the organization of Scientific Groups for specific diseases.

For prevention of viral diseases, immunization programs have been shown to be efficient and relatively inexpensive public health measures, and have been increasingly used in recent years in both developing and developed countries. Well-planned and carefully-evaluated mass immunization campaigns offer particular promise for developing countries, not only for their economical use of funds but also for the logistic advantages of such mass programs in countries having scattered rural populations, limited transportation facilities, and few or widely separated permanent health institutions. With wider public acceptance of immunization, improved delivery techniques and reagents (such as jet-injector equipment and multiple-antigen combina-

Preface XVI

tion vaccines), and more stable vaccine preparations, mass immunization campaigns are being conducted with increasing success. A dramatic example of what can be achieved is seen in the fact that serious predictions can now be made that smallpox may well be eradicated from the world by 1976 – a goal made realistic in recent years largely through the World Health Organization Smallpox Eradication Program in which mass immunization is an important tool. Foege & Edding discuss in this volume the considerable experience that has been gained recently in the conduct of such programs, and describe some of the important operational areas to be considered in planning mass immunization projects.

The serodiagnosis of viral infections has been made more reliable and efficient over the past decade through the development of micro-techniques, the standardization of test methods, wider availability of improved viral antigens and antisera, and automation of certain procedures. The review by SCHMIDT & LENNETTE in this volume constitutes an updating and extension of their chapter on the same topic published in 1961; it deals chiefly with new developments which have contributed to the diagnosis of human viral infections by serologic techniques.

Helper-dependent viruses, which are unable to replicate without the presence of another virus, have been of unusual interest ever since they were first recognized. This interest stems not only from the intrinsic significance of this phenomenon in terms of the nature of viruses, but also from the fact that defectiveness and helper-dependence were found to be characteristic of certain oncogenic viruses and have been explored as a possible key factor in oncogenesis. The opportunity to study a helper-dependent satellite virus model in a relatively simple system was provided by the recent isolation of a satellite, helper-dependent bacteriophage. Barrett, Calendar, Gibbs, Goldstein, Lindovist & Six, who have conducted much of the investigation of this phage, review the status of knowledge regarding its properties and life cycle, and discuss the potential implications for animal virology and viral oncology.

High resolution electron microscopy of thin-section preparations of virus-infected cells, correlated with accurate infectivity assays, contributes greatly to understanding not only of the structure of virus particles but also of their morphogenesis. Highshi, one of the pioneers in these studies, has updated and extended his previous review, which appeared in 1959. Selected illustrative material has been retained from the earlier version, and the author has added important new text sections and electron micrographs on virus development.

Preface XVII

In the final chapter of the volume, the Editor reports on progress in classification and nomenclature of animal viruses. In the schematic diagrams showing separation of RNA- and DNA-containing viruses into major groups on the basis of physical and chemical properties, consideration has been given to certain new findings concerning some of the groups and to proposals for group names coming into general use but not yet officially approved. Also included is a tabulation of virus groups in terms of the polymerases which they induce and/or carry.

Readers of this series are encouraged to write regarding topics that they recommend for review, and also to offer suggestions for authors who might be invited to prepare such reviews. Topics requiring more lengthy coverage than would be available in this series may be proposed for inclusion as a single volume in the companion series, Monographs in Virology.

JOSEPH L. MELNICK
Department of Virology
and Epidemiology
Baylor College of Medicine
Houston, Tex. 77025 (USA)

### Contents

Pref	ace	. XIII
	Role of Viruses in the Etiology of Congenital Malformations. BLATTNER, RUSSELL J.; WILLIAMSON, ALICE P. and HEYS, FLORENCE (Houston, Tex.)	
I.	Introduction	1
II.	Rubella Virus	
III.	Cytomegalovirus	14
IV.	Herpesvirus hominis	16
V.	Other Viruses Suspected of Causing Congenital Defects	17
VI.	Characteristics of Infections Causing Congenital Defects	
VII.	Animal Viruses Causing Congenital Defects and Experimental Studie Animal Models	
	Coxsackievirus Infections of the Newborn	42
I.	Introduction	43
II.	Outbreaks of Encephalomyocarditis Neonatorum Associated with Coxsa	ckie
	B Virus Infections	46
III.	Source of Infection	48
IV.	Clinical Features	48
	A. Course of Illness	49
	B. Electrocardiographic Changes	50
	C. Meningoencephalitis	50
	D. Hepatitis	50
	E. Radiography	50
	F. Laboratory Tests	51
	G. Outcome of Illness	51

• •				
	Contents		•	VI
V.	Pathological Findings			51
	A. Macroscopic Appearances			<b>52</b>
	B. Microscopic Findings			52
VI.	Virological Studies			56
	A. Isolation of Virus			56
	B. Types of Coxsackievirus Concerned			57
	C. Monkey Pathogenicity of Strains		٠.	58
	Epidemiology			58
VIII	.Preventive Measures			60
IX.	Summary			61
X.	References		• •	61
	The second of			
	Virus Myocardiopathy		•	63
	LERNER, A. MARTIN and Wilson, Francis M. (Detroit, Mich.)			
I.	Introduction			64
II.	Primary Myocardial Disease			65
ш.	Epidemiology.			65
	Clinical Correlates			67
	A. Criteria for Diagnosis			67
	B. Nomenclature: Acute and Chronic Phases,			69
	Benign and Virulent Types	•		•
	C. Enteroviruses and Myocardiopathy			69
	D. Virus Myocardiopathy			71
	1. Finding in Acute Phase			71
	2. Sequelae in Man			72
v.	Antibodies in Virus Myocardiopathy			73
VI.	Experimental Studies			75
	A. Myocardiopathy, Including Factors of Augmentation			75
	B. Interferon.			82
	C. Valvulitis, Valvular Deformity			84
	D. Electron Microscopy			84
	E. Other Studies (Aplastic Crises and Fetal Wastage)			85
VII.	Summary			85
VIII	.References			86
	Cytomegaloviruses of Man and Animals		•	92
	Plummer, Gordon (Maywood, Ill.)			
Intr	oduction			92
Vin	ises to be Reviewed			93
	on Structure			94
Sarr	plogic Relationships			96
	avior in Tissue Cultures			97

Contents	VII
Epidemiology	100
Human Cytomegalovirus	100
Animal Cytomegaloviruses	103
Tissues Infected in the Host Body	105
	105
Human Cytomegalovirus	105
Animal Cytomegaloviruses	
Clinical Effects	109
Human Cytomegalovirus	109
Animal Cytomegaloviruses	113
Comment	114
References	115
Viruses of the Respiratory Tract	126
I. Introduction	127
A. Criteria for Including a New Agent as a Respiratory Virus	128
	129
B. Pathogenesis and Vaccination	
II. Myxoviruses	131
A. Two Groupings of Myxoviruses	131
1. True Myxoviruses	131
2. Pseudomyxoviruses	131
B. Characteristics	131
C. Influenza (True Myxovirus)	132
1. Laboratory	133
2. Vaccination	133
3. Summary	134
D. Parainfluenza Viruses	134
1. Laboratory	134
2. Summary	136
E. Pseudomyxoviruses.	136
1. Laboratory	136
2. Summary	137
III. Rhinoviruses	137
	137
and the state of t	138
	139
	139
D. Summary	
IV. Adenoviruses	140
A. Introduction.	140
B. Adenovirus Diseases	141
1. Pharyngoconjunctival Fever	141
2. Acute Respiratory Disease (ARD)	141
3. Conjunctivitis and Keratoconjunctivitis	143
4. Acute Febrile Pharyngitis	144

C. Studies of Adenoviruses in Volunteers			
D. Vaccines         146           E. Laboratory         147           V. Coronaviruses         148           A. History         148           B. Diseases         148           VI. Summary         149           VII. References         149           The Programme of the World Health Organization in Medical Virology           COCKBURN, W. CHARLES (Geneva)         159           L. Introduction         160           II. The WHO Reference Centres         162           A. The World Influenza Centre and the International Influenza Center for the Americas         163           B. National Influenza Centres         163           C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma         165           1. International Reference Centres         165           2. Regional Reference Centres         165           3. Relations between Reference Centres         165           3. Relations between Reference Centres and National Virus Laboratories         166           D. WHO Virus Collaborating Laboratories         166           E. Meetings of Directors of Virus Reference Centres         167           F. Contributions Made by Reference Centres         167           F. Contributions Made by Reference C		Contents	VIII
D. Vaccines         146           E. Laboratory         147           V. Coronaviruses         148           A. History         148           B. Diseases         148           VI. Summary         149           VII. References         149           The Programme of the World Health Organization in Medical Virology           COCKBURN, W. CHARLES (Geneva)         159           L. Introduction         160           II. The WHO Reference Centres         162           A. The World Influenza Centre and the International Influenza Center for the Americas         163           B. National Influenza Centres         163           C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma         165           1. International Reference Centres         165           2. Regional Reference Centres         165           3. Relations between Reference Centres         165           3. Relations between Reference Centres and National Virus Laboratories         166           D. WHO Virus Collaborating Laboratories         166           E. Meetings of Directors of Virus Reference Centres         167           F. Contributions Made by Reference Centres         167           F. Contributions Made by Reference C		C. Studies of Adenoviruses in Volunteers	145
E. Laboratory  V. Coronaviruses	į		146
V. Coronaviruses         148           A. History         148           B. Diseases         148           VI. Summary         149           VII. References         149           The Programme of the World Health Organization in Medical Virology           COCKBURN, W. CHARLES (Geneva)         159           I. Introduction         160           II. The WHO Reference Centres         162           A. The World Influenza Centre and the International Influenza Center for the Americas         163           B. National Influenza Centres         163           C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses         165           Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma         165           1. International Reference Centres         165           2. Regional Reference Centres         165           3. Relations between Reference Centres and National Virus Laboratories         166           D. WHO Virus Collaborating Laboratories         166           E. Meetings of Directors of Virus Reference Centres         167           F. Contributions Made by Reference Centres         167           II. WHO Virus Reagents Programme         167           A. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses         168 <t< td=""><td>•</td><td></td><td>147</td></t<>	•		147
A. History       148         B. Diseases       148         VI. Summary       149         VII. References       149         The Programme of the World Health Organization in Medical Virology         COCKBURN, W. CHARLES (Geneva)       159         COCKBURN, W. CHARLES (Geneva)       160         II. Introduction       160         II. The WHO Reference Centres       162         A. The World Influenza Centres       163         B. National Influenza Centres       163         C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses       163         C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses       165         2. Regional Reference Centres       165         2. Regional Reference Centres       165         3. Relations between Reference Centres and National Virus Laboratories       166         D. WHO Virus Collaborating Laboratories       166         E. Meetings of Directors of Virus Reference Centres       167         F. Contributions Made by Reference Centres       167         II. WHO Virus Reagents Programme       167         A. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168	V.		148
B. Diseases	••		148
VI. Summary 149 VII. References 149  The Programme of the World Health Organization in Medical Virology 159 COCKBURN, W. CHARLES (Geneva)  I. Introduction 160 II. The WHO Reference Centres 162 A. The World Influenza Centre and the International Influenza Center for the Americas 163 B. National Influenza Centres 163 C. Reference Centres 67 C. Reference Centres 77 C. Regional Reference Centres 165 2. Regional Reference Centres 165 3. Relations between Reference Centres 165 C. Metory Collaborating Laboratories 165 D. WHO Virus Collaborating Laboratories 165 E. Meetings of Directors of Virus Reference Centres 167 F. Contributions Made by Reference Centres 167 A. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses 2. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses 168 2. Prototype Strains of Arboviruses 169 B. Viral Antisera 169 2. Respiratory Virus Antisera 169 2. Respiratory Virus Antisera 170 3. Arbovirus Antisera 170 4. Mycoplasma Antisera 170 5. Viral Antigens 171 6. Antigens 171 6. Autigens 171 6. Supply of Reagents . 171 6. Supply of Reagents . 172 6. Supply of Reagents . 172 6. Supply of Reagents . 172 6. Vicalection, Analysis and Dissemination of Information 172			
The Programme of the World Health Organization in Medical Virology	VI.		
Virology           COCKBURN, W. CHARLES (Geneva)           I. Introduction         160           II. The WHO Reference Centres         162           A. The World Influenza Centre and the International Influenza Center for the Americas         163           B. National Influenza Centres         163           C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses         165           Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma         165           1. International Reference Centres         165           2. Regional Reference Centres         165           3. Relations between Reference Centres and National Virus Laboratories         166           D. WHO Virus Collaborating Laboratories.         166           E. Meetings of Directors of Virus Reference Centres         167           F. Contributions Made by Reference Centres         167           F. Contributions Made by Reference Centres         167           II. WHO Virus Reagents Programme         167           A. Prototype Strains of Viruses         168           1. Prototype Strains of Arboviruses         168           2. Prototype Strains of Arboviruses         168           3. Characterization of Rhinoviruses         169           B. Viral Antisera         170           1. Enterovirus			149
II. The WHO Reference Centres  A. The World Influenza Centre and the International Influenza Center for the Americas  B. National Influenza Centres  C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma  1. International Reference Centres  1. International Reference Centres  2. Regional Reference Centres  3. Relations between Reference Centres and National Virus Laboratories  D. WHO Virus Collaborating Laboratories  E. Meetings of Directors of Virus Reference Centres  167  F. Contributions Made by Reference Centres  167  A. Prototype Strains of Viruses  1. Prototype Strains of Viruses  2. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses  2. Prototype Strains of Arboviruses  3. Characterization of Rhinoviruses  168  3. Characterization of Rhinoviruses  169  1. Enterovirus Antisera  109  1. Enterovirus Antisera  2. Respiratory Virus Antisera  3. Arbovirus Antisera  109  1. Enterovirus Antisera  110  3. Arbovirus Antisera  111  4. Mycoplasma Antisera  112  C. Viral Antigens  111  1. Arbovirus Antigens  112  D. Supply of Reagents  112  IV. Collection, Analysis and Dissemination of Information  172		Virology	159
II. The WHO Reference Centres  A. The World Influenza Centre and the International Influenza Center for the Americas  B. National Influenza Centres  C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma  1. International Reference Centres  1. International Reference Centres  2. Regional Reference Centres  3. Relations between Reference Centres and National Virus Laboratories  D. WHO Virus Collaborating Laboratories  E. Meetings of Directors of Virus Reference Centres  167  F. Contributions Made by Reference Centres  167  A. Prototype Strains of Viruses  1. Prototype Strains of Viruses  2. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses  2. Prototype Strains of Arboviruses  3. Characterization of Rhinoviruses  168  3. Characterization of Rhinoviruses  169  1. Enterovirus Antisera  109  1. Enterovirus Antisera  2. Respiratory Virus Antisera  3. Arbovirus Antisera  109  1. Enterovirus Antisera  110  3. Arbovirus Antisera  111  4. Mycoplasma Antisera  112  C. Viral Antigens  111  1. Arbovirus Antigens  112  D. Supply of Reagents  112  IV. Collection, Analysis and Dissemination of Information  172			
A. The World Influenza Centre and the International Influenza Center for the Americas	I.		160
Americas	II.	The WHO Reference Centres	162
B. National Influenza Centres C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma. 165 1. International Reference Centres 165 2. Regional Reference Centres 165 3. Relations between Reference Centres and National Virus Laboratories 166 D. WHO Virus Collaborating Laboratories 166 E. Meetings of Directors of Virus Reference Centres 167 F. Contributions Made by Reference Centres 167 III. WHO Virus Reagents Programme 167 A. Prototype Strains of Viruses 168 1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses 168 2. Prototype Strains of Arboviruses 168 3. Characterization of Rhinoviruses 169 B. Viral Antisera 169 1. Enterovirus Antisera 169 2. Respiratory Virus Antisera 170 3. Arbovirus Antisera 170 a) Grouping Sera and Ascitic Fluids 171 4. Mycoplasma Antisera 171 C. Viral Antigens 171 1. Arbovirus Antigens 171 2. Antigens for Other Viruses 172 IV. Collection, Analysis and Dissemination of Information 172			
C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma. 165 1. International Reference Centres 165 2. Regional Reference Centres 165 3. Relations between Reference Centres and National Virus Laboratories 166 D. WHO Virus Collaborating Laboratories 166 E. Meetings of Directors of Virus Reference Centres 167 F. Contributions Made by Reference Centres 167 III. WHO Virus Reagents Programme 167 A. Prototype Strains of Viruses 168 1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses 168 2. Prototype Strains of Arboviruses 169 3. Characterization of Rhinoviruses 169 B. Viral Antisera 169 1. Enterovirus Antisera 169 2. Respiratory Virus Antisera 170 3. Arbovirus Antisera 170 b) Type-Specific Sera and Ascitic Fluids 171 4. Mycoplasma Antisera 171 C. Viral Antigens 171 1. Arbovirus Antigens 171 2. Antigens for Other Viruses 172 D. Supply of Reagents 172 IV. Collection, Analysis and Dissemination of Information 172		Americas	163
Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma. 165  1. International Reference Centres 165  2. Regional Reference Centres 165  3. Relations between Reference Centres and National Virus Laboratories 166  D. WHO Virus Collaborating Laboratories 166  E. Meetings of Directors of Virus Reference Centres 167  F. Contributions Made by Reference Centres 167  III. WHO Virus Reagents Programme 167  A. Prototype Strains of Viruses 168  1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses 168  2. Prototype Strains of Arboviruses 168  3. Characterization of Rhinoviruses 169  B. Viral Antisera 169  1. Enterovirus Antisera 169  2. Respiratory Virus Antisera 170  a) Grouping Sera and Ascitic Fluids 170  b) Type-Specific Sera and Ascitic Fluids 171  4. Mycoplasma Antisera 171  C. Viral Antigens 171  1. Arbovirus Antigens 171  2. Antigens for Other Viruses 171  D. Supply of Reagents 172  IV. Collection, Analysis and Dissemination of Information 172			163
1. International Reference Centres       165         2. Regional Reference Centres       165         3. Relations between Reference Centres and National Virus Laboratories       166         D. WHO Virus Collaborating Laboratories       166         E. Meetings of Directors of Virus Reference Centres       167         F. Contributions Made by Reference Centres       167         F. Contributions Made by Reference Centres       167         III. WHO Virus Reagents Programme       167         A. Prototype Strains of Viruses       168         1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         a) Grouping Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		C. Reference Centres for Arboviruses, Enteroviruses, Respiratory Viruses	
2. Regional Reference Centres       165         3. Relations between Reference Centres and National Virus Laboratories       166         D. WHO Virus Collaborating Laboratories       166         E. Meetings of Directors of Virus Reference Centres       167         F. Contributions Made by Reference Centres       167         III. WHO Virus Reagents Programme       167         A. Prototype Strains of Viruses       168         1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		Other than Influenza, Mycoplasmas, Rickettsioses and Trachoma	165
3. Relations between Reference Centres and National Virus Laboratories D. WHO Virus Collaborating Laboratories E. Meetings of Directors of Virus Reference Centres 167 F. Contributions Made by Reference Centres 168 III. WHO Virus Reagents Programme 169 A. Prototype Strains of Viruses 1 Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses 2 Prototype Strains of Arboviruses 1 Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and Miscellaneous Viruses 1 Prototype Strains of Enteric Prototype and		1. International Reference Centres	165
D. WHO Virus Collaborating Laboratories       166         E. Meetings of Directors of Virus Reference Centres       167         F. Contributions Made by Reference Centres       167         III. WHO Virus Reagents Programme       167         A. Prototype Strains of Viruses       168         1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       170         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		2. Regional Reference Centres	165
E. Meetings of Directors of Virus Reference Centres.       167         F. Contributions Made by Reference Centres.       167         III. WHO Virus Reagents Programme       167         A. Prototype Strains of Viruses       168         1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       170         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		3. Relations between Reference Centres and National Virus Laboratories	166
F. Contributions Made by Reference Centres       167         III. WHO Virus Reagents Programme       167         A. Prototype Strains of Viruses       168         1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		D. WHO Virus Collaborating Laboratories	166
III. WHO Virus Reagents Programme       167         A. Prototype Strains of Viruses       168         1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		E. Meetings of Directors of Virus Reference Centres	167
A. Prototype Strains of Viruses       168         1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		F. Contributions Made by Reference Centres	167
1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses       168         2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172	III.	WHO Virus Reagents Programme	167
2. Prototype Strains of Arboviruses       168         3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		A. Prototype Strains of Viruses	168
3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172	,	1. Prototype Strains of Enteric, Respiratory and Miscellaneous Viruses	168
3. Characterization of Rhinoviruses       169         B. Viral Antisera       169         1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		2. Prototype Strains of Arboviruses	168
1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172			169
1. Enterovirus Antisera       169         2. Respiratory Virus Antisera       170         3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		B. Viral Antisera	169
3. Arbovirus Antisera       170         a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		1. Enterovirus Antisera	169
a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		2. Respiratory Virus Antisera	170
a) Grouping Sera and Ascitic Fluids       170         b) Type-Specific Sera and Ascitic Fluids       171         4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172		3. Arbovirus Antisera	170
4. Mycoplasma Antisera       171         C. Viral Antigens       171         1. Arbovirus Antigens       171         2. Antigens for Other Viruses       171         D. Supply of Reagents       172         IV. Collection, Analysis and Dissemination of Information       172			170
C. Viral Antigens		b) Type-Specific Sera and Ascitic Fluids	171
1. Arbovirus Antigens		4. Mycoplasma Antisera	171
1. Arbovirus Antigens		C. Viral Antigens	171
D. Supply of Reagents			171
D. Supply of Reagents		2. Antigens for Other Viruses	171
IV. Collection, Analysis and Dissemination of Information			172
	IV.		172
		A. Viruses Other than Arboviruses	173
B. Arboviruses			174

V.	Training
VI.	Epidemic Aid
	Expert Committees and Scientific Groups
	Team for Special Studies in Virology
IX.	Definition and Anticipation of Problems of International Public Health
v	Importance.
X.	Specific Activities
	A. Inter-Country Collaborative Studies on Specific Subjects
XI.	B. Single-Country Studies on Specific Subjects
	Regional Programmes
	Summary
LYTY	References
	Annex 2
	Annex 3
	Annex 4
[.	Introduction
	Introduction
	History of Mass Immunization Programs
I. II.	History of Mass Immunization Programs
	History of Mass Immunization Programs.  A. Variolation
II.	History of Mass Immunization Programs.  A. Variolation
II.	History of Mass Immunization Programs.  A. Variolation
II.	History of Mass Immunization Programs.  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning
II.	History of Mass Immunization Programs.  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign
I.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities
I.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics
I.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance
II.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations
I.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations  1. Vaccines
I.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations  1. Vaccines  2. Advance Publicity
I.	History of Mass Immunization Programs.  A. Variolation  B. Smallpox Vaccination.  C. Yellow Fever  D. BCG  Operational Considerations.  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations  1. Vaccines  2. Advance Publicity  3. Vaccine Delivery Methods
I.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations  1. Vaccines  2. Advance Publicity  3. Vaccine Delivery Methods  a) Bifurcated Needle
II.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations  1. Vaccines  2. Advance Publicity  3. Vaccine Delivery Methods  a) Bifurcated Needle  b) Needle and Syringe
II.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations  1. Vaccines  2. Advance Publicity  3. Vaccine Delivery Methods  a) Bifurcated Needle  b) Needle and Syringe  c) Jet Injectors
II.	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations  1. Vaccines  2. Advance Publicity  3. Vaccine Delivery Methods  a) Bifurcated Needle  b) Needle and Syringe  c) Jet Injectors  4. Age of Vaccine Recipients
	History of Mass Immunization Programs  A. Variolation  B. Smallpox Vaccination  C. Yellow Fever  D. BCG  Operational Considerations  A. Organization and Planning  1. Background Information  2. Type of Campaign  3. Establishment of Vaccine Priorities  4. Staffing and Logistics  B. Surveillance  C. Operations  1. Vaccines  2. Advance Publicity  3. Vaccine Delivery Methods  a) Bifurcated Needle  b) Needle and Syringe  c) Jet Injectors

IV.		217
	A. Smallpox Eradication and Measles Control in West and Central Africa .	217
	1. History of the Program	217
	2. Smallpox and Measles in West and Central Africa	218
	3. Mass Vaccination	222
	a) Smallpox	222
	b) Measles	224
	c) Other Antigens	229
	4. Surveillance and Epidemiologic Investigations	229
	5. Assessment	231
	6. Maintenance	231
	B. Global Smallpox Eradication Program	231
	1. History	231
	2. Geographic Communica	
٧.	2. Geographic Summaries	236
	Future Possibilities	239
VI.	Summary	240
VII	. Acknowledgements	240
VII	I. References	240
	Advances in the Serodiagnosis of Viral Infections	244
I.	Introduction	245
II.	Neutralization Tests	246
	A. Neutralization Tests in Monolayer Cell Culture Systems	247
	B. Metabolic Inhibition (Colorimetric) Neutralization Tests	248
	C. Plaque Reduction Neutralization Tests	249
	D. The Persistent, Non-Neutralizable Virus Fraction	251
	E. Enhancement of Viral Neutralization by Heat-Labile Serum Components	252
	F. Viral Inhibitors in Sera	253
	G. Identification of Viral Isolates by Neutralization Tests Employing Immune	200
	Serum Pools	254
III.	Hemagglutination Inhibition Tests.	254
	A. Adenoviruses	256
	B. Arboviruses	258
	C. Coronaviruses	261
	D. Enteroviruses	
		261
	E. Myxoviruses and Paramyxoviruses	263
	F. Reoviruses	265
	G. Rhabdoviruses	265
***	H. Rubella Virus	265
IV.	Hemadsorption Inhibition Tests	266
V.	Mixed Hemadsorption	267
VI.	Immune Adherence	267
VII.	Indirect Hemagglutination	268

	Contents	ХI
VIII	I. Hemaggregation	269
IX.	Platelet Aggregation	270
X.	Complement Fixation	270
XI.	Immunofluorescent Staining	274
	A. Virus Identification	275
	B. Antibody Assays	278
XII	Precipitation, Agglutination and Flocculation	279
	A. Flocculation and Agglutination	274
	B. Immunodiffusion.	280
	C. Immunoelectrophoresis	283
	D. Counter-Immunoelectrophoresis	284
	E. Radioisotope Precipitation	
	L. Radioisotope Freeiphation	284
	Helper-Dependent Bacteriophage P4: A Model Satellite Virus and	
	its Implications for Animal Virology	309
	BARRETT, KATHLEEN; CALENDAR, RICHARD; GIBBS, WARREN; GOLDSTEIN, RICHARD N. (Berkeley, Calif.); LINDQVIST, BJORN and SIX, ERICH (Iowa City, Ia.)	
I. II.	Introduction	310 310 310 311 312 312
	E. Arrangement of the Genes on P2 Phage DNA and the Normal Control	
***	P2 Gene Expression	313
III.	Helper-Dependent Bacteriophage P4.	314
	A. Isolation and Properties	314
	B. Functions performed by Satellite Phage P4 in the Absence of Helper	315
	1. DNA Replication	315
	2. Lysogenization	315
	3. Lysogenic Conversion	315
	C. Exploitation of the Helper Genome by P4	316
	1. Replication of the Helper DNA is Not Required	316
	2. Immunity Repression of the Helper Prophage Remains Intact	316
	3. Transactivation of the Helper Genes by P4	317
IV.	A Comparison of Helper-Dependent Phage P4 with Some Defective Animal Viruses	217
		317
	A. Avian Sarcoma Virus  B. The Moloney Strain of Murine Sarcoma Virus.	318
	C. The Friend Strain of Murine Leukemia Virus	318
	D. Adeno-Associated Satellite Virus	319
V.	Implications for Animal Virology	320
••	A. The Complexity of Helper-Dependent Viruses	321
		321

	B. Possible Tumor Viruses with Properties Similar to Satellite Phage P4. C. Transactivation of Latent Genes
VI.	Summary
	. Acknowledgements
VII	I. References . :
	Electron Microscopy of Viruses in Thin Sections of Cells Grown
	Culture
	HIGASHI, NOBORU (Kyoto)
I.	Introduction ,
II.	Electron Microscopy of Poxviruses in Thin Sections of Cultured Cells
	A. Growth Cycle Experiments
	B. Conventional Optical Microscopy
	C. Electron Microscopy
	1. Virus-to-Cell Adsorption
	2. Engulfment and Uncoating
	3. Formation of Inclusions
	4. Viral Development in an Early Stage of Infection
	5. Formation of Mature Viral Particles
	6. Discussion
m	Electron Microscopy of the Development of Chikungunya Virus in Thin So
	tions of Green Monkey Kidney Stable (VERO) Cells
	A. Growth Curve Experiments
	B. Formation of Inclusions and Emergence of Virus Precursors within the
	C. Virions within Vacuoles
	D. Virus Assembly at the Cell Surface
	E. The Morphology of CHV
	F. Electron Microscopic Observation of CHV-RNA
	*
117	G. Discussion
IV.	
.,	Cultured Cells
V.	References

Progr. med. Virol., vol. 15, pp. 1-41 (Karger, Basel 1973)

## Role of Viruses in the Etiology of Congenital Malformations<sup>1</sup>

RUSSELL J. BLATTNER, ALICE P. WILLIAMSON and FLORENCE M, HEYS Department of Pediatrics, Baylor College of Medicine, Houston, Texas

#### Contents

I.	Introduction
	Rubella Virus
	Cytomegalovirus
	Herpesvirus hominis
	Other Viruses Suspected of Causing Congenital Defects
VI.	Characteristics of Infections Causing Congenital Defects
VII.	Animal Viruses Causing Congenital Defects and Experimental Studies in
	Animal Models

#### I. Introduction

In recent years, while fetal and infant morbidity and mortality resulting from other causes have declined, the incidence of congenital malformations has remained high. Although the figures vary according to the types of studies made by different investigators it has been estimated that each year, in the United States alone, as many as 500,000 fetal deaths and 62,000 liveborn deaths may be associated with congenital defects, while approximately 15 million surviving persons have one or more birth defects which are

<sup>1</sup> The early volumes of Progress in Medical Virology are now out of print. Rather than re-printing the entire volume, certain timely articles have been selected for up-dating. The previous review on this subject was written by Drs. BLATTNER and Heys and appeared in volume 3.